SHANGHAI, November 22, 2023 — Shares of Innovent Biologics jumped as much as 21% Wednesday after the Chinese biotech firm struck a $350 million deal with Eli Lilly to develop and commercialize its cancer drug, IBI305.
Lilly’s $350 Million Bet on Chinese Biotech
A new partnership between Eli Lilly and Innovent Biologics signals growing confidence in Chinese pharmaceutical innovation.
- Eli Lilly will pay Innovent Biologics $350 million upfront for exclusive rights to IBI305 outside of China.
- IBI305 is a bispecific antibody targeting both PD-1 and CTLA-4, two key immune checkpoint proteins.
- The deal highlights the increasing trend of major pharmaceutical companies partnering with Chinese biotech firms.
- Innovent Biologics’ shares experienced a significant surge following the announcement.
The collaboration allows Eli Lilly to expand its oncology pipeline with a promising new therapy, while providing Innovent Biologics with substantial funding and validation. This partnership demonstrates how pharmaceutical companies are increasingly looking to China for innovative cancer treatments.
A Deep Dive into IBI305
IBI305 is a bispecific antibody designed to simultaneously block PD-1 and CTLA-4, two proteins that prevent the immune system from attacking cancer cells. By targeting both pathways, IBI305 aims to unleash a more potent immune response against tumors. The drug is currently in Phase 3 clinical trials for non-small cell lung cancer and other solid tumors.
Did you know? Bispecific antibodies are a relatively new class of cancer drugs that have shown promising results in clinical trials.
Financial Details of the Deal
Under the terms of the agreement, Eli Lilly will pay Innovent Biologics $350 million upfront for exclusive rights to develop and commercialize IBI305 outside of China. Innovent Biologics will also be eligible to receive additional milestone payments and royalties on future sales. The deal does not include rights to IBI305 within mainland China, where Innovent Biologics will continue to develop and commercialize the drug independently.
Growing Trend of Pharma Partnerships with Chinese Firms
This partnership is the latest in a series of collaborations between major pharmaceutical companies and Chinese biotech firms. Several factors are driving this trend, including the lower cost of research and development in China, the increasing quality of Chinese biotech innovation, and the growing demand for new cancer treatments. The Chinese market also presents a significant opportunity for growth.
What Does This Mean for Investors?
The deal is a positive development for both companies. For Eli Lilly, it provides access to a promising new drug candidate with the potential to generate significant revenue. For Innovent Biologics, it provides a substantial financial boost and validation of its research and development capabilities. The surge in Innovent Biologics’ share price reflects investor optimism about the deal.
The stock jumped as high as 17.8% in Hong Kong trading, and was up 15.7% as of 10:34 a.m. local time.
Keep reading
